Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Sep 27, 2022

Keywords

ClinConnect Summary

This clinical trial is testing a new MRI technique to help doctors understand how brain tumors change after treatment. Specifically, it aims to figure out whether any growth in the tumor is due to the cancer getting worse or is just a side effect of the treatment called stereotactic radiosurgery (SRS). This could help doctors make better decisions about patient care.

To participate in this study, you must be at least 18 years old and able to understand what the study involves. You could either be a healthy volunteer with no cancer or a patient with at least one brain metastasis (a type of tumor that has spread to the brain) that is larger than 1 cm. Participants can expect to undergo some MRI scans and may receive SRS treatment if they are patients. It's important to note that pregnant or breastfeeding women, as well as those with certain medical conditions, cannot participate. Overall, this study could lead to improved ways of monitoring and treating brain tumors in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Healthy volunteers \[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\] will be entered into the study if they meet the following criteria:
• • Age ≥ 18 years
• • Able to understand and give informed consent
• • No known cancer diagnosis
• Patients \[for Study Aim 1 (SA1)\] will be entered into the study if they meet the following criteria:
• • Age ≥ 18 years
• • Able to understand and give informed consent
• • At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
• Patients \[for Study Aim 3 (SA3)\] will be entered into the study if they meet the following criteria:
• • Age ≥ 18 years
• • Able to understand and give informed consent
• • At least one untreated brain metastasis \> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)
• • Planned SRS treatment
• Exclusion Criteria:
• Healthy volunteers (SA1 \& SA2) and patients (SA1 \& SA3) exclusion criteria:
• • Pregnant or breastfeeding women
• • Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
• • Age \< 18 years